Ποια είναι η τιμή για Hillstream BioPharma, Inc. (HILS)

Η τιμή για Hillstream BioPharma, Inc. (HILS) είναι $0.181

Ποια είναι η κεφαλαιοποίηση αγοράς για Hillstream BioPharma, Inc. (HILS)

Η κεφαλαιοποίηση αγοράς για Hillstream BioPharma, Inc. (HILS) είναι $2.03M

Hillstream BioPharma, Inc. (HILS) Τιμή και Κεφαλαιοποίηση Αγοράς

Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.

Η τιμή για HILS	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$485,347 $2.03M	NVDA	$5.452T	+268,147,441.41%
$399,720 $2.03M	AAPL	$4.490T	+220,839,422.92%
$370,554 $2.03M	GOOG	$4.162T	+204,725,924.73%
$327,283 $2.03M	MSFT	$3.676T	+180,819,067.80%
$252,209 $2.03M	AMZN	$2.833T	+139,341,764.47%

Η τιμή για HILS

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$485,347 $2.03M